BioSpace News Archive

Artelo Biosciences, Inc. today announced its continued sponsorship of The William A. Devane Early Career Investigator Award at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

Imagine a day when a urine test could inform a doctor precisely why a kidney transplant patient was experiencing organ rejection and suggest the best medication for specifically addressing the problem.

Abcam plc, a global leader in the supply of life science research tools, confirmed that it has received a letter of undertaking from Dr. Jonathan Milner withdrawing his notice dated May 30, 2023 which required the Company to call an Extraordinary General Meeting of its shareholders to consider certain resolutions proposed by him.

Clarity Pharmaceuticals is pleased to announce the establishment of a Center of Excellence at the Idaho Accelerator Center, a research facility operated by Idaho State University, for Targeted Copper Theranostics.

Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.

Triumvira Immunologics today announced that it will be presenting clinical data on its lead asset AC01-HER2 for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors at the 2023 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, June 28 - July 1, 2023.

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ending June 30, 2023 on Thursday, July 27, 2023 at 7:30 a.m. EDT.

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial.

Shasqi, Inc. announced the expansion of its Click Activated Protodrugs Against Cancer platform with a pivotal manuscript describing the preclinical development of SQ2201, a novel cancer therapy.

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA on 6 June 2023 regarding the Company’s acquisition of Thor Medical AS, with approval of the Transaction from the Company’s annual general meeting as one of the closing conditions.